The inhibition of FLT3 signaling by sorafenib or quizartinib with the concomitant use of PRI-724 to block the transcriptional activity of β-catenin improved the effects against acute myeloid leukemia stem cells [33]. The gene discussed is FLT3; the disease is acute myeloid leukemia.